• 1. Alternative mixtures to R-600a. Theoretical assessment and experimental energy evaluation of binary mixtures in a commercial cooler: Mélanges alternatifs au R-600a. évaluation théorique et évaluation énergétique expérimentale de mélanges binaires dans un refroidisseur commercial.
  DanielCalleja-Anta,DanielSánchez,LauraNebot-Andres,RamónCabello,RodrigoLlopis
• 2. An ionic liquid promoted microwave-hydrothermal route towards highly photoluminescent carbon dots for sensitive and selective detection of iron(iii)?
  Ruili Liu,Mengping Gao,Jing Zhang,Zhilian Li,Jinyang Chen,Ping Liu,Dongqing Wu RSC Adv., 2015,5, 24205-24209
• 3. Aggregation-induced emission leading to two distinct emissive species in the solid-state structure of high-dipole organic chromophores?
  Felix Witte,Philipp Rietsch,Nithiya Nirmalananthan-Budau,Florian Weigert,Jan P. G?tze,Ute Resch-Genger,Siegfried Eigler,Beate Paulus Phys. Chem. Chem. Phys., 2021,23, 17521-17529
• 4. An alkynylboronatecycloaddition strategy to functionalised benzyne derivatives?
  James D. Kirkham,Patrick M. Delaney,George J. Ellames,Eleanor C. Row,Joseph P. A. Harrity Chem. Commun., 2010,46, 5154-5156
• 5. An investigation of new infrared nonlinear optical material: BaCdSnSe4, and three new related centrosymmetric compounds: Ba2SnSe4, Mg2GeSe4, and Ba2Ge2S6?
  Kui Wu,Zhihua Yang,Shilie Pan Dalton Trans., 2015,44, 19856-19864

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzimidazoles Sulfinylbenzimidazoles

Introduction to 3-Hydroxyomeprazole (CAS No. 176219-02-6)

3-Hydroxyomeprazole, identified by the chemical compound code CAS No. 176219-02-6, is a significant intermediate in the pharmaceutical industry, particularly in the synthesis of proton pump inhibitors (PPIs). These compounds play a crucial role in modulating gastric acid secretion, making them essential for treating various gastrointestinal disorders. The introduction of 3-Hydroxyomeprazole into the synthetic pathway has revolutionized the production of highly effective and targeted therapeutic agents.

The chemical structure of 3-Hydroxyomeprazole features a substituted benzimidazole core, which is a hallmark of many PPIs. This core structure is responsible for its potent inhibitory effects on the hydrogen/potassium ATPase enzyme, commonly known as the proton pump, located on the gastric parietal cells. By selectively inhibiting this enzyme, 3-Hydroxyomeprazole and its derivatives significantly reduce gastric acid production, thereby alleviating symptoms associated with conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, and hypersecretory states.

Recent advancements in medicinal chemistry have highlighted the importance of optimizing the synthesis and pharmacokinetic properties of 3-Hydroxyomeprazole. Researchers have been focusing on developing more efficient synthetic routes that minimize side reactions and improve yield. These efforts have led to the discovery of novel catalysts and reaction conditions that enhance the overall process efficiency.

In addition to its role as a key intermediate, 3-Hydroxyomeprazole has been studied for its potential pharmacological applications beyond gastric acid suppression. Emerging research suggests that it may possess anti-inflammatory and antioxidant properties, which could make it valuable in treating inflammatory bowel disease (IBD) and other chronic inflammatory conditions. These findings open up new avenues for therapeutic development and highlight the versatility of 3-Hydroxyomeprazole.

The pharmacokinetic profile of 3-Hydroxyomeprazole is another area of active investigation. Studies have shown that its derivatives exhibit improved bioavailability and longer half-life compared to earlier generations of PPIs. This enhancement is attributed to modifications in the molecular structure that enhance solubility and reduce metabolic degradation. Such improvements are critical for achieving sustained therapeutic effects and reducing dosing frequency.

Regulatory agencies worldwide have stringent guidelines for the approval of new pharmaceutical compounds derived from intermediates like 3-Hydroxyomeprazole. Compliance with these regulations ensures that patients receive safe and effective treatments. The synthesis and purification processes must adhere to Good Manufacturing Practices (GMP) to guarantee consistency and quality across batches.

The environmental impact of producing 3-Hydroxyomeprazole is also a growing concern. Efforts are underway to develop greener synthetic methods that reduce waste generation and minimize energy consumption. These sustainable practices not only benefit the environment but also contribute to cost reduction in drug manufacturing.

Future research directions for 3-Hydroxyomeprazole include exploring its potential in combination therapies with other gastrointestinal drugs. Such combinations could offer synergistic effects, improving patient outcomes in complex conditions like GERD with concurrent motility disorders. Additionally, investigating its role in non-gastrointestinal diseases may uncover new therapeutic uses beyond its current applications.

The development of novel formulations based on 3-Hydroxyomeprazole derivatives is another exciting area of research. Formulations such as delayed-release tablets and orally disintegrating films aim to enhance patient compliance by providing convenient and effective dosing options. These innovations address common challenges faced by patients taking traditional PPIs, such as difficulty swallowing pills or inconsistent absorption rates.

In conclusion, 3-Hydroxyomeprazole (CAS No. 176219-02-6) is a vital compound in modern pharmaceuticals, with significant implications for treating gastrointestinal disorders. Its synthesis, pharmacological properties, and potential applications continue to be subjects of extensive research. As scientific understanding advances, new opportunities for optimizing its use are likely to emerge, further solidifying its importance in therapeutic strategies worldwide.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)